About 4.4 billion prescriptions filled in the U.S. in 2016; Sanofi and Ablynx reach I-O deal; biotech M&A slows in H1
Millian, a former Sanofi and Merck executive, on marketing new therapies in the MS market.
The cancer and immunology drug may help patients with a condition that affects two people in every one million.
Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused
The drugmaker inks deal with Novo Nordisk to access its biologic discovery research platform.
The FDA granted the drug Priority Review status just last week.
The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.
Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.
AstraZeneca's Nexium now has generic competition, toxicity worries researchers about new cancer approaches and a former Pfizer exec will now lead an e-cigarette company.
News flowing from Bristol-Myers Squibb and Merck show the two companies may fight for elbow room among lung cancer patients with drugs that have already started building credibility in other indications.
The specialty biopharma firm says it's hiring new commercial managers after a buying spree.
The ISIS Pharmaceuticals collaboration will focus on gastrointestinal autoimmune disorders.
A focus on the existing Yervoy prescribing community could help Bristol-Myers Squibb drive sales of Opdivo past rival Keytruda, one analyst argues.
The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.
Merck's Keytruda and BMS's Opdivo reverse tumor growth in Hodgkin's patients studies.
Early trials of Venetoclax, formerly known as ABT-199, indicate the experimental drug execs consider an oncology cornerstone continues to show promise.
The company says ABP 510 hit its primary endpoint in an adalimumab comparison.
The FDA approved the drug previously known as pembrolizumab, now known as Keytruda, for patients with unresectable or metastatic melanoma who have taken Bristol-Myers Squibb's Yervoy (ipilimumab).
A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.
Roche backs away from Chugai but embraces InterMune, Merck rumored on track to score first PD-1 approval, a new Ebola strain may have surfaced and JNJ scoops up experimental anti-TNF.
The drugmaker has paired up with Incyte and CytomyX in two separate deals.
The FDA's approval of Takeda's Entyvio puts the drugmaker in the ulcerative colititis and Crohn's mix of prescription treatments.
Sales of its big diabetes franchise rose 3% vs. the same period last year, while drops in Singulair and Nasonex revenue marked the quarter. The company is slated to reveal pipeline progress next week.
The drugmaker's purchase of private biotech CoStim Pharmaceuticals comes with a host of experimental immuno-oncology agents.
The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.
The two will explore cancer-attacking nanobodies.
Friday's no-nivolumab news event disappointed some, but analysts generally rooted for BMS, which saw year-end sales fall 7%, because of anticipated immuno-oncology success.
Merck and Celgene are exploring a combination that could solidify their immuno-oncology footholds.
Phase III results of its Crohn's and ulcerative colitis medication show positive patient response in a category among patients who have exhausted other options.